Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Collins

Showing results (1-10 of 247) with videos related to

Pageof 25
Sort By:
Future Virology|October 27, 2022
Advances in the development of vaccines against Marburg and Ebola virusesPeter L Collins, Alexander Bukreyev
Current Opinion in Molecular Therapeutics|January 30, 2008
Newcastle disease virus as a vaccine vector for humansAlexander Bukreyev, Peter L Collins
Expert Review of Vaccines|December 22, 2009
Filovirus vaccines: what challenges are left?Alexander Bukreyev, Peter L Collins
Journal of Virology|November 16, 2004
Reevaluation of the virulence of prototypic strain 15 of pneumonia virus of miceChristine D Krempl, Peter L Collins
Proceedings of the American Thoracic Society|August 23, 2005
New generation live vaccines against human respiratory syncytial virus designed by reverse geneticsPeter L Collins, Brian R Murphy
World Journal of Gastroenterology|November 18, 2015
Immune dysfunction in acute alcoholic hepatitisAshwin D Dhanda, Peter L Collins
Journal of Virology|October 12, 2007
Viral and host factors in human respiratory syncytial virus pathogenesisPeter L Collins, Barney S Graham
The Journal of Clinical Investigation|July 3, 2002
Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse geneticsBrian R Murphy, Peter L Collins
Journal of Virology|May 22, 2002
The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivoMichael N Teng, Peter L Collins
Virology|June 19, 2002
Respiratory syncytial virus: reverse genetics and vaccine strategiesPeter L Collins, Brian R Murphy
Pageof 25

Showing results (1-10 of 247) with videos related to

Sort By:
Pageof 25
Future Virology|October 27, 2022
Advances in the development of vaccines against Marburg and Ebola virusesPeter L Collins, Alexander Bukreyev
Current Opinion in Molecular Therapeutics|January 30, 2008
Newcastle disease virus as a vaccine vector for humansAlexander Bukreyev, Peter L Collins
Expert Review of Vaccines|December 22, 2009
Filovirus vaccines: what challenges are left?Alexander Bukreyev, Peter L Collins
Journal of Virology|November 16, 2004
Reevaluation of the virulence of prototypic strain 15 of pneumonia virus of miceChristine D Krempl, Peter L Collins
Proceedings of the American Thoracic Society|August 23, 2005
New generation live vaccines against human respiratory syncytial virus designed by reverse geneticsPeter L Collins, Brian R Murphy
World Journal of Gastroenterology|November 18, 2015
Immune dysfunction in acute alcoholic hepatitisAshwin D Dhanda, Peter L Collins
Journal of Virology|October 12, 2007
Viral and host factors in human respiratory syncytial virus pathogenesisPeter L Collins, Barney S Graham
The Journal of Clinical Investigation|July 3, 2002
Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse geneticsBrian R Murphy, Peter L Collins
Journal of Virology|May 22, 2002
The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivoMichael N Teng, Peter L Collins
Virology|June 19, 2002
Respiratory syncytial virus: reverse genetics and vaccine strategiesPeter L Collins, Brian R Murphy
Pageof 25